Moreover, inhibition of the HER2 signal significantly reduced, at both the mRNA and protein level, the expression of PD-L1 and PD-L2 in tumour cells, thus implicating HER2 in the modulation of innate immune resistance [86]. The gene discussed is PDCD1LG2; the disease is neoplasm.